ValueQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSelling/general/admin expenses300 M341 M400 M351 M338 M1.43 BResearch & development81 M94 M92 M89 M93 M368 MOperating income-402 M100 M73 M2 M-583 M-408 MNon-Operating Income, Total——————Interest expense, net of interest capitalized46 M40 M48 M52 M80 M220 MNon-Operating Income, excl. Interest Expenses——————Unusual income/expense——————Pretax income-51 M60 M25 M-50 M-259 M-224 MEquity in earnings——————Taxes-43 M-7 M14 M-16 M17 M8 MNon-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations-8 M67 M11 M-34 M-276 M-232 MDiscontinued operations——————Net income-8 M67 M11 M-34 M-276 M-232 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders-8 M67 M11 M-34 M-276 M-232 MBasic earnings per share (Basic EPS)-0.020.140.02-0.07-0.56-0.47Diluted earnings per share (Diluted EPS)-0.010.130.02-0.07-0.55-0.47Average basic shares outstanding494 M495.1 M496.6 M496.8 M496.4 M1.98 BDiluted shares outstanding497.3 M499.1 M500.1 M496.8 M496.4 M1.99 BEBITDA67 M233 M205 M126 M-493 M71 MEBIT-97 M72 M36 M-50 M-667 M-609 MCost of revenue501 M509 M528 M530 M555 M2.12 BOther cost of goods sold——————Depreciation & amortization (cash flow)164 M161 M169 M176 M174 M680 M
Elanco Animal Health Incorporated
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.